FDA Revisits Old Issues For Novartis' COPD Drug Indacaterol At Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The Pulmonary-Allergy Drugs Advisory Committee is being asked whether safety and efficacy have been established for two doses of the chronic obstructive pulmonary disease treatment Arcapta, the same problem that caused an earlier "complete response" letter.